ArticleFrontiers in immunology2025
Liquid-liquid phase separation in gastric cancer: identifying novel biomarkers and therapeutic targets through gene signature analysis.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multi-site sequencing supports dual-track evolution and identifies candidate metastasis-associated factors in gastric cancer ovarian metastasis.Clinical and translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: Liquid-liquid phase separation (LLPS) plays an important role in the development of many tumors, including gastric cancer, but its prognostic value is unclear. The aim of this study was to explore the prognostic significance of LLPS-related genes in gastric cancer to provide a basis for improving the accuracy of prognostic prediction and finding potential therapeutic targets in gastric cancer. Methods: Clinical and transcriptomic data of gastric cancer were downloaded from TCGA and GEO databases, and LLPS-related genes were extracted from PhaSepDB. Unsupervised clustering was used to identify molecular subtypes based on LLPS gene expression. LLPS gene features were constructed and validated by LASSO Cox regression, and their staging prediction value was also evaluated by machine learning methods. Key genes were validated by qRT-PCR, Western blot, immunofluorescence, and functional experiments (shRNA knockdown, CCK-8, clone formation, and scratch assay). Results: Twenty LLPS-associated genes showed significant mRNA expression, copy number variation, somatic mutation, and interaction network alterations in gastric cancer tissues. Two LLPS molecular isoforms with different survival outcomes and immune microenvironment characteristics were identified. A four-gene LLPS prognostic signature consisting of Conclusion: This study revealed the important role of LLPS in gastric cancer, and the constructed four-gene LLPS signature is expected to be a novel biomarker for prognostic assessment and treatment of gastric cancer. PSPC1 plays a key role in gastric cancer progression, and has the value of a potential therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.